CTNM (Contineum Therapeutics) Cash-to-Debt : 366.25 (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Contineum Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2024 was 366.25.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Contineum Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Contineum Therapeutics's Cash-to-Debt or its related term are showing as below:

CTNM' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.08 Med: 161.05 Max: 366.25
Current: 366.25

During the past 3 years, Contineum Therapeutics's highest Cash to Debt Ratio was 366.25. The lowest was 8.08. And the median was 161.05.

CTNM's Cash-to-Debt is ranked better than
85.53% of 1493 companies
in the Biotechnology industry
Industry Median: 6.2 vs CTNM: 366.25

Contineum Therapeutics Cash-to-Debt Historical Data

The historical data trend for Contineum Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Contineum Therapeutics Cash-to-Debt Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

14.06

8.08

218.86

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash-to-Debt	Get a 7-Day Free Trial				N/A	120.54	218.86	201.55	366.25

Competitive Comparison of Contineum Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Contineum Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Cash-to-Debt falls into.

Contineum Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Contineum Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	125.19	/	(0.464	+	0.108)
	=	218.86

Contineum Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	218.653	/	(0.484	+	0.113)
	=	366.25

Contineum Therapeutics (NAS:CTNM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Contineum Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.